Physician profile
Rakesh Prasad
NPI 1487639746
$7,871.96
in general payments reported to CMS, 2019-2025
50 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $982 · 2021: $1,895 · 2022: $1,264 · 2023: $633 · 2024: $891 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,703 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.91 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,795.01 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $727.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $633.57 | 2019-2025 | Jardiance |
| Abbvie INC. | $423.18 | 2021-2025 | |
| Novo Nordisk INC | $372.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $330.33 | 2019-2025 | Jardiance, Emgality, Kisunla |
| Amgen INC. | $315.08 | 2019-2023 | Otezla, Repatha |
| Esperion Therapeutics, INC. | $305.54 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $292.90 | 2019-2025 | |
| Pfizer INC. | $252.46 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $243.76 | 2019-2022 | |
| Boston Scientific Corporation | $220.18 | 2024-2025 | Bodyguardian, Watchman Access System, Cds - Mct/Cem Monitoring |
| Abbott Laboratories | $219.38 | 2022-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $148.04 | 2019-2021 | |
| Astellas Pharma US INC | $138.22 | 2023-2024 | Veozah |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.